Highlights Egetis Therapeutics AB

Equities

EGTX

SE0003815604

Market Closed - Nasdaq Stockholm Other stock markets 16:29:36 14/05/2024 BST			5-day change	1st Jan Change
6.13 ^SEK	+0.49%		+0.49%	+9.86%

05-03	Egetis Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-22	Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Egetis Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-03	CI
Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
Egetis Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Egetis Therapeutics AB Provides Update on Disease Awareness and the Expanded Access Program for Tiratricol in the USA	12-13	CI
Egetis Therapeutics Grants Fujimoto Pharmaceutical Exclusive Rights to Emcitate in Japan; Stock Rises	11-10	MT
Egetis Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Egetis Therapeutics AB Announces Ema Validation of Marketing Authorisation Application for Emcitate for the Treatment of Mct8 Deficiency	27/10/23	CI
Egetis Therapeutics Seeks Marketing Authorization for Genetic Disorder Treatment in Europe	09/10/23	MT
Egetis Therapeutics AB Submits Marketing Authorisation Application for Emcitate for Treatment of MCT8 Deficiency to the European Medicines Agency	09/10/23	CI
Egetis Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	22/08/23	CI
Egetis Therapeutics AB Announces First Patient Included and Second Site Activated in the Pivotal Retriact Trial	24/07/23	CI
Egetis Therapeutics AB Announces Site Activation in the Pivotal Retriact Trial for Emcitate	28/06/23	CI
Egetis Terminates Discussions Regarding Potential Acquisition	24/05/23	CI
Egetis Therapeutics Ends Talks for Potential Takeover	24/05/23	MT
Egetis Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2023	26/04/23	CI
Egetis Comments on M&A Rumors	30/03/23	CI
Egetis comments on market rumors	30/03/23	AQ
Egetis Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2022	22/02/23	CI
Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	22/02/23	CI
Egetis Therapeutics AB Submits Expanded Access Program for Emcitate® in the USA	07/12/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Egetis Therapeutics AB

Equities

EGTX

SE0003815604

Highlights

Filters